Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 86 Results

Title
Intervention Indication Therapeutic Area Year Actions
Zolbetuximab for previously untreated advanced gastric or gastro-oesophageal junction adenocarcinoma Zolbetuximab (IMAB362) Gastro-oesophageal junction cancer Gastrointestinal Cancer 2022 View  |  Download
Zanubrutinib for treating marginal zone lymphoma Zanubrutinib (BGB-3111; Brukinsa) Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma Zanubrutinib (BGB-3111; Brukinsa) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma Zanubrutinib (BGB-3111; Brukinsa) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Vutrisiran for treating hereditary transthyretin amyloidosis Vutrisiran (ALN-TTRSC02) Amyloidosis Endocrine, nutritional and metabolic disorders 2022 View  |  Download
Vedolizumab for treating active pouchitis Vedolizumab (Entyvio; LDP-02; MLN0002) Pouchitis Gastroenterology 2022 View  |  Download
Tislelizumab with etoposide and carboplatin or cisplatin for treating small-cell lung cancer Carboplatin (Paraplatin) , Cisplatin (Platinol) , Etoposide , Tislelizumab (BGB-A317; BGBA-317) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2022 View  |  Download
Tislelizumab with chemotherapy for previously
untreated advanced oesophageal squamous cell
carcinoma
Tislelizumab (BGB-A317; BGBA-317) Oesophageal squamous cell carcinoma Gastrointestinal Cancer 2022 View  |  Download
Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma Chemotherapy , Tislelizumab (BGB-A317; BGBA-317) Gastric cancer , Gastro-oesophageal junction adenocarcinoma Gastrointestinal Cancer 2022 View  |  Download
Tislelizumab in combination with Paclitaxel, Cisplatin, and Radiotherapy for Oesophageal cancer Cisplatin (Platinol) , Paclitaxel (Taxol; paclitaxel albumin) , Tislelizumab (BGB-A317; BGBA-317) Squamous cell carcinoma (SCC) Head and Neck Cancer 2022 View  |  Download
1 2 3 8 9
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications